Baxter International Inc.
BAX evidence brief
What we can confirm
- BioSniper Score:
- 8.0 / 10
- Market Cap:
- $12.06B
- Lead Asset:
- floseal hemostatic matrix
What it means
What to watch
Prepared research question
What matters most for BAX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · BAX
Baxter International Inc. (BAX) is a global medical products company focused on hospital and critical-care products, having recently completed a strategic divestiture of its Kidney Care business and reporting $2.96B in revenue for the period ended June 30, 2026.
Key risk: Thin net profit margin
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$12.06B
Cash Runway
—
Lead Asset
floseal hemostatic matrix
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial for Baxter International Inc..
Baxter International Inc. (BAX) is a global medical products company focused on hospital and critical-care products, having recently completed a strategic divestiture of its Kidney Care business and reporting $2.96B in revenue for the period ended June 30, 2026.
- Completed the sale of the Kidney Care business (now Vantive Health LLC) on January 31, 2025, generating approximately $3.3 billion of net after-tax proceeds [sec · filed 2026-03-23].
- Cash and equivalents of $2,150.0M as of 2026-06-30 [sec].
- Total revenue of $2,960.0M and net income of $126.0M as of 2026-06-30 [sec].
- Shareholders' equity of $6,206.0M as of 2026-06-30 [sec].
- Pipeline includes approved products such as Preveleak surgical sealant, Seprafilm bioresorbable membrane, and PerClot polysaccharide hemostatic system [pipeline].
What works
- Strong cash position of $2,150.0M as of 2026-06-30 provides financial flexibility for operations and investments [sec].
- The $3.3B net proceeds from the Kidney Care sale completed a strategic transformation and strengthened the balance sheet [sec · filed 2026-03-23].
- Products support care of more than 350 million patients annually, indicating broad market reach [sec · filed 2026-03-23].
What to weigh
- Net income of $126.0M on $2,960.0M revenue as of 2026-06-30 implies a relatively thin net profit margin of about 4.3% [sec].
- The pipeline section lists numerous oncology competitors (e.g., AstraZeneca, Pfizer) in overlapping spaces, suggesting a highly competitive environment for hemostatic and surgical sealant products [pipeline].
- No new late-stage pipeline candidates beyond approved products are detailed in the provided chunks, which may indicate limited near-term product catalysts [pipeline].
From the filings
Quoted directly from source documents.
Sale of Kidney Care business generated $3.3B net after-tax proceeds
“Completed the sale of the Kidney Care business, now known as Vantive Health LLC, to Carlyle Group Inc. on January 31, 2025, generating approximately $3.3 billion of net after‑tax proceeds.”
SEC filings · March 23, 2026
Products support over 350 million patients annually
“each year, our essential, market‑leading products help support the care of more than 350 million patients worldwide”
SEC filings · March 23, 2026
Catalyst timeline
- 2026-07-30 · Earnings: Baxter to Host Second-Quarter 2026 Financial Results Conference Call for Investors — Baxter will host a conference call to discuss its second-quarter 2026 financial results.
Risks & what to watch (3)›
Key risks
- Thin net profit margin — Net income of $126M on $2,960M revenue (≈4.3% margin) as of 2026-06-30 [sec].
- Intense competitive landscape — Pipeline shows 142 competitors including major pharma for hemostatic/sealant products [pipeline].
- Limited late-stage pipeline — No new late-stage candidates beyond approved products in provided chunks [pipeline].
What to watch
- Second-quarter 2026 financial results conference call scheduled for July 30, 2026 [catalyst].
- Integration and performance after the Kidney Care divestiture and use of the $3.3B proceeds [sec · filed 2026-03-23].
- Any new pipeline developments or regulatory actions for approved products like PerClot (PDUFA date May 8, 2024) [catalyst].
Sources: Catalysts · Competitor trials · Pipeline · SEC filings · Generated October 9, 2026 · How we verify sources →
Run Baxter International Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Baxter International Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 2.19 · 0% dilution
Lead: Approved
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Short Interest
as of May 20, 2026- % of float
- 10.7%
- Days to cover
- 4.5
- Shares short
- 35,078,391
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
BAX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Baxter International Inc.?
Baxter International Inc. (BAX) is a global medical products company focused on hospital and critical-care products, having recently completed a strategic divestiture of its Kidney Care business and reporting $2.96B in revenue for the period ended June 30, 2026.
Who is the CEO of Baxter International Inc.?
Mr. Andrew P. Hider is the chief executive officer of Baxter International Inc. (BAX).
Where is Baxter International Inc. headquartered?
Baxter International Inc. (BAX) is headquartered in Deerfield, IL, United States.
What therapeutic areas does Baxter International Inc. focus on?
Baxter International Inc. develops therapies across Oncology, Reproductive.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.